{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:23:21Z","timestamp":1772990601951,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.leukres.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:27:16Z","timestamp":1473424036000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands"],"prefix":"10.1016","volume":"50","author":[{"given":"Hedwig M.","family":"Blommestein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke J.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-7433","authenticated-orcid":false,"given":"Pepijn","family":"Vemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet F.M.","family":"van Abeelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.F.M. Ward","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.09.005_bib0005","series-title":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Statistics. Chronic Lymphocytic Leukemia\/small Lymphocytic Lymphoma","year":"2015"},{"key":"10.1016\/j.leukres.2016.09.005_bib0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ejca.2011.06.053","article-title":"Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989\u20132008","volume":"48","author":"van den Broek","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2016.09.005_bib0015","series-title":"Exploring the Iceberg of Chronic Lymphocytic Leukaemia. Towards a Better Estimation of the Burden and Quality of Care for CLL Patients in the Netherlands","author":"van den Broek","year":"2014"},{"key":"10.1016\/j.leukres.2016.09.005_bib0020","author":"HOVON","year":"2015"},{"key":"10.1016\/j.leukres.2016.09.005_bib0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.09.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.528.528","article-title":"Ofatumumab+chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)","volume":"122","author":"Hillmen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.09.005_bib0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2013.10.029","article-title":"Real-world costs of chronic lymphocytic leukaemia in the Netherlands","volume":"38","author":"Holtzer-Goor","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.09.005_bib0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jval.2015.12.018","article-title":"Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia","volume":"19","author":"Becker","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.leukres.2016.09.005_bib0045","unstructured":"NICE. National Institute for Health and Care Excellence, Process and methods guides. The guidelines manual. 6 (2012)."},{"key":"10.1016\/j.leukres.2016.09.005_bib0050","unstructured":"L. Hakkaart-van Roijen, S. Tan, C. Bouwmans, Guidelines for cost-effectiveness research. [In Dutch: Handleiding voor kostenonderzoek. Methode en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2010] (2010)."},{"key":"10.1016\/j.leukres.2016.09.005_bib0055","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.leukres.2016.09.005_bib0060","series-title":"Appendix to Dias, Sutton, Ades and Welton. Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials Medical Decision Making 2013.33(5)607-617","author":"Dias","year":"2013"},{"key":"10.1016\/j.leukres.2016.09.005_bib0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.leukres.2016.09.005_bib0070","series-title":"Statistics Netherlands. Statline, Den Haag\/Heerlen","year":"2015"},{"key":"10.1016\/j.leukres.2016.09.005_bib0075","first-page":"321","article-title":"A population based registry' for hemato-oncology","volume":"7","author":"Huijgens","year":"2010","journal-title":"Ned. Tijdschr. Hematol."},{"key":"10.1016\/j.leukres.2016.09.005_bib0080","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-015-0260-4","article-title":"A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry","author":"Blommestein","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.leukres.2016.09.005_bib0085","first-page":"1","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","author":"Kosmas","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.09.005_bib0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3111\/13696990903149479","article-title":"Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia","volume":"12","author":"Bouwmans","year":"2009","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.leukres.2016.09.005_bib0095","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.09.005_bib0100","unstructured":"Dutch National Health Care Institute (ZIN), Cost-effectiveness in practice [in Dutch: Kosten-effectiviteit in de praktijk] (2015)."},{"key":"10.1016\/j.leukres.2016.09.005_bib0105","unstructured":"M.M. Versteegh The iMTA Disease Burden Calculator. Version 1.3 beta. 2016. (accessed July, 2016)."},{"key":"10.1016\/j.leukres.2016.09.005_bib0110","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2016.09.005_bib0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents","volume":"38","author":"Gaultney","year":"2013","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T19:40:46Z","timestamp":1668627646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":23,"alternative-id":["S0145212616301904"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}